主页 > 生命科学 >
【文摘发布】meta分析结果：黄体生成素释放激素
DOI:10.1016/S0140-6736(07)60778-8
TITLE: Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials
LHRH-agonists in Early Breast Cancer Overview group
Summary
Background
Several trials have been done to assess treatment of premenopausal breast cancer with luteinising-hormone-releasing hormone (LHRH) agonists, but results have been inconclusive, especially for patients with hormone-receptor-positive cancer.
Methods
We collected individual patients' data from published trials and did analyses focused on women with tumours positive for oestrogen receptor, progesterone receptor, or both. The main endpoints were recurrence and death after recurrence.
Findings
We obtained data for 11 906 premenopausal women with early breast cancer randomised in 16 trials. When used as the only systemic adjuvant treatment, LHRH agonists did not significantly reduce recurrence (28·4% relative reduction, 95% CI consistent with 50·5% reduction to 3·5% increase, p=0·08) or death after recurrence (17·8%, 52·8% reduction to 42·9% increase, p=0·49) in hormone-receptor-positive cancers. Addition of LHRH agonists to tamoxifen, chemotherapy, or both reduced recurrence by 12·7% (2·4–21·9, p=0·02); and death after recurrence by 15·1% (1·8–26·7, p=0·03). LHRH agonists showed similar efficacy to chemotherapy (recurrence 3·9% increase, 7·7% reduction to 17·0% increase; death after recurrence 6·7% reduction, 20·7% reduction to 9·6% increase; both not significant). No trials had assessed an LHRH agonist versus chemotherapy with tamoxifen in both arms. LHRH agonists were ineffective in hormone-receptor-negative tumours.
Interpretation
LHRH agonists provide an additional class of agents for treatment of premenopausal women with hormone-receptor-positive breast cancer. Optimum duration of use is unknown. 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 首先要对题目提个意见，agonist是激动剂而非阻断剂，antagonist是拮抗剂
RESOURCE: The Lancet 2007; 369:1711-1723
来源：《柳叶刀》 2007; 369:1711-1723
DOI:10.1016/S0140-6736(07)60778-8
DOI:10.1016/S0140-6736(07)60778-8
TITLE: Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials
LHRH-agonists in Early Breast Cancer Overview group
题目：meta分析结果：黄体生成素释放激素激动剂辅助治疗激素受体阳性的绝经前乳腺癌患者的疗效
Summary 概要
Background 背景
Several trials have been done to assess treatment of premenopausal breast cancer with luteinising-hormone-releasing hormone (LHRH) agonists, but results have been inconclusive, especially for patients with hormone-receptor-positive cancer.
数项实验已被开展用于评估黄体生成素释放激素（LHRH）激动剂对绝经前乳腺癌患者的治疗效果，但结果并不确定，尤其是对那些激素受体阳性的癌症患者。
Methods 方法
We collected individual patients' data from published trials and did analyses focused on women with tumours positive for oestrogen receptor, progesterone receptor, or both. The main endpoints were recurrence and death after recurrence.
我们从已发表的实验中收集个体病人的资料数据并对雌激素受体阳性、孕酮受体阳性或两者均阳性的女性肿瘤患者进行集中分析。主要终点为（肿瘤）复发或复发后死亡。
Findings 结果
We obtained data for 11 906 premenopausal women with early breast cancer randomised in 16 trials.
我们收集了随机分布于16项实验中的11906名患早期乳腺癌的绝经前女性的资料。
When used as the only systemic adjuvant treatment, LHRH agonists did not significantly reduce recurrence (28•4% relative reduction, 95% CI consistent with 50•5% reduction to 3•5% increase, p=0•08) or death after recurrence (17•8%, 52•8% reduction to 42•9% increase, p=0•49) in hormone-receptor-positive cancers.
当被单独作为一种系统辅助治疗手段时，LHRH激动剂并不能显著降低激素受体阳性癌症的复发率（相对风险降低率28.4%，95%可信区间为50.5%降低到3.5%上升，P=0.08）或复发后死亡率（17.8%，-52.8%~42.9%，P=0.49）。
Addition of LHRH agonists to tamoxifen, chemotherapy, or both reduced recurrence by 12•7% (2•4–21•9, p=0•02); and death after recurrence by 15•1% (1•8–26•7, p=0•03).
在他莫西芬、化疗或两者合用的治疗中加用LHRH激动剂可降低12.7%的复发率(2.4–21.9, p=0.02)和15.1%的复发后死亡率。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-06 17:11
医学,生命科学网